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Nuclear localizationThe Fas associated death domain protein (FADD) is the key adaptormolecule of the apoptotic signal triggered by
death receptors of the TNF-R1 superfamily. Besides its crucial role in the apoptotic machinery, FADD has proved
to be important in many biological processes like tumorigenesis, embryonic development or cell cycle progres-
sion. In a process to decipher the regulatory mechanisms underlying FADD regulation, we identiﬁed the anti-
apoptotic kinase, CK2, as a new partner and regulator of FADD sub-cellular localization. The blockade of CK2 ac-
tivity induced FADD re-localization within the cell. Moreover, cytoplasmic FADDwas increased when CK2βwas
knocked down. In vitro kinase and pull down assays conﬁrmed that FADD could be phosphorylated by the CK2
holoenzyme. We found that phosphorylation is weak with CK2α alone and optimal in the presence of stoichio-
metric amounts of CK2α catalytic and CK2β regulatory subunit, showing that FADDphosphorylation is undertak-
en by the CK2 holoenzyme in a CK2β-driven fashion. We found that CK2 can phosphorylate FADD on the serine
200 and that this phosphorylation is important for nuclear localization of FADD. Altogether, our results show for
the ﬁrst time that multifaceted kinase, CK2, phosphorylates FADD and is involved in its sub-cellular localization.
This work uncovered an important role of CK2 in stable FADD nuclear localization.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Since its discovery in 1995 by Chinnayian et al. as an adaptor of the
Fas signaling pathway, the Fas associated death domain protein
(FADD) has been described as the main transducer of death domain-
containing receptors like TNF-R1 (tumor necrosis factor receptor 1),
DR3 (death receptor 3), TRAIL-R1 (TNF-related apoptosis-inducing li-
gand, DR4), and TRAIL-R2 (DR5) [1–5]. Upon activation of the receptors
by their respective ligands, cytoplasmic FADD binds to the intra-
cytoplasmic tail of these receptors via its death domain (DD) and2, Casein kinase 2; TBB, 4,5,6,7-
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er, 105, Boulevard de l'Hôpital,transduces the signal to caspase-8 via homotypic binding of their re-
spective death effector domain. As a result, downstream effector
caspases are activated and lead to subsequent cell death [6]. Besides
itsmajor role in apoptosis, FADDhas been described as a crucial element
in many important biological processes like embryonic development,
proliferation, cell cycle progression, tumor development, innate immu-
nity and autophagy [7–13]. All these functions are ﬁnely tuned via dif-
ferent modes of regulation like phosphorylation and differential
localizations [14–16]. While a cytosolic localization is necessary for the
pro-apoptotic function of FADD, the role of FADD in cell cycle progres-
sion, T cell proliferation or genome surveillance, is dependent on its nu-
clear localization [17,18]. The exact mechanism of how FADD could
participate in anti-apoptoptic processes is still unclear but evidence
have shown that phosphorylation of FADD on the residue serine 194
is necessary for the localization of the protein to the nucleus. The
CK1α kinase has been identiﬁed as the one responsible for FADD phos-
phorylation and it was shown that CK1α and phosphorylated FADD co-
localize in the nucleus during mitosis. The authors suggested that the
association with CK1α rather than the phosphorylation itself deter-
mined FADD sub-cellular localization [19]. Though it is known that
CK1α controls FADD phosphorylation and relocalization to the nuclear
Fig. 1. Imaging of FADD sub-cellular localization upon TBB treatment. THP-1 cells were stainedwith anti-FADDpAb coupled (green) andDAPI (blue). The cells were incubated in the pres-
ence of 50 μMTBB and at different time points. The cells werewashedwith PBS, deposited on slides using cytospin, ﬁxed and labeledwith the indicated antibodies. A) Panel a) is the rep-
resentative image of untreated THP-1 cells and b) is the representative image of THP-1 cells treated for 14 h with TBB. Data shown are representative of 2 independent experiments and
represent the appearance of themajority of cells under a stated condition. Bars represent 10 μm. B) Quantiﬁcation of nuclear FADDwas assessed for each conditions (treated or untreated)
using the mask option of Image J. C) Representative image of comparison of FADD localization in (a) untreated cells and cells treated with CX-4945 (20 μg/ml) for (b) 2 h and (c) 6 h.
D) Quantiﬁcation of nuclear FADD assessed using themask option of Image J. Several image sectionswere analyzed so that at least 40–50 exploitable cells could be used for quantiﬁcation.
Bars represent 15 μm.*p ≤ 0.05, **p ≤ 0.01 (n=2). E) Subcellular fractionation of THP-1 cells. Actin and p84were used as loading control for cytoplasmic and nuclear extracts respectively.
Graphs show quantiﬁcation of cytoplasmic and nuclear FADD as ratios of FADD signal over actin and p84 respectively. Error bars show SEM of two independent experiments.
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restriction to the nucleus. This restriction could allow FADD enough
time to bind to proteins involved in the anti-apoptotic activities,
named above. While searching for such potential regulatory partners
of FADD, we focused our attention on the anti-apoptotic protein kinase
CK2 [20].
CK2 kinase, formerly casein kinase II, is a highly conserved serine/
threonine protein kinase identiﬁed in all eukaryotes [20,21]. The protein
comprises two alpha catalytic subunitsα or α′ and two regulatory sub-
unitsβ that can formanheterotetrameric holoenzyme inwhich the two
β subunits dimerize to bind to the α or α′ subunits [22,23]. A variety of
studies have showed that CK2 is involved in many different cellular
processes like cell cycle progression, apoptosis, transcriptional regula-
tion, protein transport, signal transduction and viral physiopathology
[20,24–26]. CK2 localizes both in the nuclear and cytoplasmic compart-
mentswhere it interactswith awide repertoire of substrates involved in
different cellular functions. Of interest, CK2 has been implicated in apo-
ptosis inhibition, cell transformation and also protein localization[27–29]. With regard to functional inhibition of apoptosis, male mice
in which the CK2α′ subunit has been disrupted demonstrated a higher
number of apoptotic cells in testes than their littermates [30]. In the
same line, other studies have shown that CK2 could confer resistance
to TRAIL-induced apoptosis in a human model of colon carcinoma
cells and FAS sensitivity in amodel of endometrial cancer cells by upreg-
ulating the level of FLIP, a dominant negative of caspase-8 [27,31].
Studies also showed that CK2 could inhibit apoptosis by blocking
caspase cleavage. McDonnell et al. [45] showed in the murine cell line,
FL5.12, that CK2 inhibited apoptosis by phosphorylating procaspase-9
near the site of caspase-8 cleavage while Desagher et al., showed that
Bid could be phosphorylated by CK2 close to the recognition site of
caspase-8 [32]. Consistent with such anti-apoptotic activities, CK2
expression level is therefore increased in several cancers as well as
experimental tumors [33]. More speciﬁcally, nuclear localization of
CK2α was shown to be of poor prognosis in prostate cancer [34]. In
light of the anti-apoptotic activities of CK2, we investigated whether a
potential regulation of FADD via the kinase could occur.
Fig.1 (continued)
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lates FADD in a CK2β dependent fashion. Blocking CK2 activity either
with drugs or CK2β knockdown led to nuclear FADD loss and increased
extracellular FADD. This regulation of FADD sub-cellular localization
suggests that CK2 is a key component of the anti-apoptotic machinery
to retain FADD in the nucleus and away from its pro-apoptotic partners.
2. Experimental procedures
2.1. Reagents
Brefeldin A, 4,5,6,7-Tetrabromo-2-azabenzimidazole (TBB), human
recombinant FADD were purchased from Sigma (Sigma-Aldrich, Saint-
Quentin Fallavier, France). CX4945 was synthesized by Cylene Pharma-
ceuticals (San Diego, CA, USA).
2.2. Cell culture
THP-1 cells were grown in RPMI 1640 (Invitrogen) supplemented
with 10% fetal calf serum (The Cell Culture Company), 1% penicillin/
streptomycin (Gibco-BRL, Life Technologies SAS, Saint Aubin, France),
5% sodium pyruvate (Gibco), 1% Hepes (Gibco) and maintained at
37 °C in a 5% CO2 incubator. MCF10A cells were grown in DMEM-F12
Glutamax (Gibco) supplemented with 5% Horse serum, 0.025% EGF at
0.1 mg/ml, 0.05% hydrocortisone at 1 mg/ml (Sigma-Aldrich), 0.01%
cholera toxin at 1 mg/ml (Sigma-Aldrich), 0.1% insulin at 10 mg/ml
(Sigma-Aldrich) and 0.5% penicillin/streptomycin (Gibco).
2.3. Immunoﬂuorescence staining
THP-1 cells were washed once in PBS and submitted to the cytospin
technique (80,000 cells/spot) for efﬁcient immunostaining. Cells werethen ﬁxed in 4% PFA for 30 min at RT, permeabilized in 0.05 M TBS
pH 7.6 Triton 0.3% for 5 min at RT. The cells were then saturated in 10%
horse serum in TBS for 20 min at RT. In order to visualize FADD, cells
were incubated for 2 h at RT with anti-human FADD antibody (10 μg/
ml) (Calbiochem, Merck Millipore, Molsheim, France) in 0.05 M TBS
pH 7.6 followed by incubation with anti-rabbit IgG FITC-conjugated (10
μg/ml) (Santa Cruz Biotechnology, CA, USA). For triple staining of
CK2α, CK2β and FADD, cells were incubated overnight with the respec-
tive antibodies (polyclonal αCOC antibody [34], monoclonal β-M and
polyclonal anti-FADD) and for 1 h at RT with secondary antibodies
(anti-rabbit FITC) (BD Pharmingen), anti-mouse Cy5 (Abcam, Paris,
France), biotinylated anti-mouse + Streptavidin-PE (BD Pharmingen)
respectively. To assess the concentration of nuclear FADD binary images
were created and themask option used. The signal given as an amount of
pixel was indicative of FADD concentration in the nucleus; wt-MCF10A
and ΔCK2β-MCF10A were grown overnight on lab-tek chamber slide
(Nunc, Thermo-Fischer Scientiﬁc, Brebières, France), pre-coated for 6 h
at 37 °C with polylysine. The cells were allowed to grow during 2 days
before staining. Cells were then washed with PBS and stained with the
appropriate antibodies. Cells were mounted in Vectashield Mounting
Mediumwith DAPI (Vector Laboratories, Burlingame, CA, USA) and ana-
lyzed using a spinning disk confocal microscope (Leica) equipped with a
CoolSnap HQ2 camera (Photometrics, Tucson, AZ, USA). Digital pictures
were analyzed using MetaMorph 7 software (Molecular Devices, St-
Grégoire, France) and processed using ImageJ software. For nuclear/cyto-
plasmic quantiﬁcation of FADD, around 100–200 cells were counted for
each condition andmaskswere createdwith ImageJ so that only the con-
tent of the nucleus was scored and compared between the control and
the conditions treatedwith drugs. Colocalization of proteins is represent-
ed in white and was produced with the Colocalization Finder tool of
ImageJ. Pearson's correlation coefﬁcient was determined using the
JaCoP plugin.
Fig. 2. Representative images of colocalization of FADD and CK2 subunits. A) THP-1 cells were ﬁxed to slides following cytospin and were stained with anti-FADD pAb (green), anti-CK2α
mAb (orange hot), anti-CK2βmAb (red) andDAPI (blue). B) Colocalization of FADD and CK2 subunitswas assessed using the JaCoP plugin of ImageJ. Colocalized pixels are shown inwhite.
Two independent experiments have been conducted. Five ﬁelds were counted per experiment, each ﬁeld containing around forty cells. Pearson's correlation coefﬁcients have been
calculated on one representative merge images of FADD and CK2α or CK2β. Bars represent 10 μm.
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The kinase assay is based on phosphorylation of a CK2-speciﬁc
peptide substrate using the transfer of the γ-phosphate of [γ-32P] ATP
by CK2 kinase as described in [35]. Recombinant CK2 subunits were
expressed in bacteria and puriﬁed as described [46,47]. CK2 assays
were performed using a speciﬁc CK2 peptide substrate as previously de-
scribed [48]. MBP-FADD (2.5 μg) was incubated at 22 °C with 10 μM
[γ-32P] ATP and 10 mMMgCl2 in the presence of 90 ng of either oligo-
meric CK2 or 50 ng of monomeric CK2α subunit supplemented with
ﬁxed (50 ng) or varying amounts (5–40 ng) of CK2β subunit. After
5 min, the reaction was stopped with 60 μl of 4% cold trichloroacetic
acid. The proteinswere precipitated for 30min and the reactionmixture
centrifuged. The supernatant was spotted on phosphocellulose paper
and after 3 washes in cold 5% phosphoric acid, the radioactivity was
counted in scintillation liquid.2.5. Pull down assay
Extraction of THP-1 cells was done in normal lysis buffer (10 mM
Tris–HCl, 150 mM NaCl pH 7.8, 1% Nonidet P-40). Prior to the pull
down assay, Heparin-sepharose 6 Fast Flow column (GE Healthcare)
were equilibrated in 50 mM Tris–HCl pH 7.5, 0.4 M NaCl, 1 mM DTT,1% glycerol. THP-1 cell extracts were then loaded on the columns. The
latter were washed (500 μl) with the equilibration buffer and CK2 was
eluted with 300 μl of 50 mM Tris–HCl pH 7.5, 1.0 M NaCl, 1 mM DTT,
1% glycerol.
2.6. Protein extraction, dosage and Western blot
Proteins were extracted from cells using lysis buffer (10 mM Tris–
HCl, 150 mM NaCl pH 7.8, 1% Nonidet P-40), containing a mixture of
protease inhibitors (Complete, Mini, EDTA-free) (Roche Diagnostics,
Meylan, France) and phosphatase inhibitors (PhosphoStop) (Roche
Diagnostics). Protein concentration was determined using the Micro
BCA Protein Assay Kit (Thermo Fischer Scientiﬁc) and/or the Nanodrop
ND2000 (Thermo Fischer Scientiﬁc). Prior to immunoblot, 40 μg of
protein extract was heated at 100 °C for 5 min in Laemmli buffer
containing 2-β mercaptoethanol. Protein extracts (40 μg/lane) were
then separated by SDS-PAGE at 25 mA and transferred to
polyvinyledineﬂouride (PVDF) membranes by electroblotting at 125 V
for 1 h. The membrane was then blocked with TBS 0.1% Tween 20, 5%
non-fat dry milk at 37 °C for 60 min. After blocking, the membrane
was washed once with TBS (5 min), probed with anti-hFADD BD
Pharmingen (1:250 in TBS 0.1% Tween 20, 5% non-fat dry milk) and
incubated at 37 °C for 60 min. The membrane was then washed with
TBS 0.1% Tween (3 × 5 min), followed by addition of afﬁnity-puriﬁed
Table 1
CK2putative sites in FADD. Summary of the 14CK2putative sites identiﬁed in FADDby the
HPRD (Human Protein Reference Database). Potential phosphorylated serines are in bold.
Position in query protein Sequence in query protein
1 10 SVS
2 14 SLS
3 16 SSSE
4 17 SSE
5 18 SELT
6 41 SGLD
7 122 SDT
8 124 TKID
9 128 SIE
10 151 TEKE
11 194 SPMS
12 200 SDAS
13 203 STSE
14 205 SEAS
Fig. 3. CK2 directly binds and phosphorylates FADD. A)Western blotting of FADD and CK2 subunits. B) In-vitro kinase assay was performed using 2.5 μg of MBP-FADD, recombinant CK2
subunits (50 ng of CK2α and 40 ng of CK2β) or recombinant holoenzyme (90 ng) and [γ-32P] ATP and 10 mMMgCl2. Reaction mixture was transferred to phospho-cellulose paper and
phosphorylation ofMBP-FADDwasdetected by autoradiography. C)Variable concentrations of CK2β (5–40ng)were used to evaluate thenecessity of the regulatory subunit in FADDphos-
phorylation. D) CK2 was pulled-down from THP-1 cell extract using heparin-sepharose columns. The columns were washed and CK2 was recovered in elution buffer (see Materials and
methods). The resulting CK2was used for in-vitro kinase assay performed onMBP-FADD (same conditions as above) in the presence or absence of CX-4945. Phosphorylationwas detected
with autoradiography.
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(1:10,000 in TBS 0.1% Tween 20, 5% non-fat dry milk) and incubated at
37 °C for 60min. After incubation, themembranewaswashedwith TBS
0.1% Tween 20 (3× 5min). Themembranewas then incubated 1min in
ECL Prime solution (Amersham, GE Healthcare Europe GmbH, Velizy-
Villacoublay, France) and the chemoluminescent signal revealed with
the image acquisition system Fusion FX7 (Vilber Lourmat).
2.7. Identiﬁcation of CK2 phosphorylation site in FADD
To determine the phosphorylation site, 3 μg ofMBP-FADDwas phos-
phorylated by CK2 in the presence or absence of 100 μM ATP-MgCl2.
Proteins were resolved by SDS-PAGE and were stained with Coomassie
blue. Gel bands fromMBP-FADDwere excised and cut in pieces. The fol-
lowing sample incubations were performed automatically using a Free-
dom EVO150 robot (Tecan Traging AG, Switzerland). Gel pieces were
washed by 6 successive incubations of 15 min in 25 mM NH4HCO3
and in 25 mM NH4HCO3 containing 50% (v/v) acetonitrile. Gel pieces
were then dehydrated with 100% acetonitrile and incubated for
Table 2
Identiﬁcation of a phosphorylatable peptide by MS/MS. A 19 amino-acid long peptide SGAMSPMSWNSDASTSEAS was identiﬁed by MS/MS analysis. For all the queries with a number 1
rank (99.61%, 94.38%, 64.66% respectively) showed in bold, the peptide was phosphorylated on serine 200 (Sp).
Query number Rank Peptide score Peptide sequence Peptide modiﬁcation Probability assignation
2698 1 74.12 SGAMSPMSWNSpDASTSEAS Phospho (ST) 99.61%
2736 1 33.12 SGAMoxSPMSWNSpDASTSEAS Oxidation (M); Phospho (ST) 64.66%
2736 2 25.96 SGAMoxSPMSpWNSDASTSEAS Oxidation (M); Phospho (ST) 12.44%
2736 3 24.91 SGAMoxSPMSWNSDASpTSEAS Oxidation (M); Phospho (ST) 9.76%
2736 4 21.34 SGAMoxSPMSWNSDASTpSEAS Oxidation (M); Phospho (ST) 4.29%
2736 5 20.01 SGAMSPMoxSWNSpDASTSEAS Oxidation (M); Phospho (ST) 3.16%
2736 6 15.12 SGAMoxSpPMSWNSDASTSEAS Oxidation (M); Phospho (ST) 1.02%
2752 1 52.62 SGAMoxSPMoxSWNSpDASTSEAS 2 Oxidation (M); Phospho (ST) 94.38%
2752 2 37.29 SGAMoxSPMoxSpWNSDASTSEAS 2 Oxidation (M); Phospho (ST) 2.77%
2752 3 34.89 SGAMoxSPMoxSWNSDASpTSEAS 2 Oxidation (M); Phospho (ST) 1.59%
2752 4 33.32 SGAMoxSPMoxSWNSDASTpSEAS 2 Oxidation (M); Phospho (ST) 1.11%
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the dark with 55 mM iodoacetamide in 25 mM NH4HCO3. Alkylation
was stopped by adding 10 mM DTT in 25 mM NH4HCO3 and mixing
for 10 min. Gel pieces were then washed again by incubation in
25 mM NH4HCO3 before dehydration with 100% acetonitrile. 0.5 μg of
modiﬁed trypsin (Promega, sequencing grade) in 25 mM NH4HCO3
was added to the dehydrated gel pieces for an overnight incubation at
37 °C. Peptides were then extracted from gel pieces in three 15 min se-
quential extraction steps in 30 μl of 50% acetonitrile, 30 μl of 5% formic
acid and ﬁnally 30 μl of 100% acetonitrile. The pooled supernatants
were then dried under vacuum. The dried extracted peptides were re-
suspended in 5% acetonitrile and 0.1% triﬂuoroacetic acid and analyzed
by online nanoLC-MS/MS (Ultimate 3000, Dionex and LTQ-Orbitrap
Velos pro, Thermo Fischer Scientiﬁc). The nanoLC method consisted in
a 30-minute gradient ranging from4% to 45% acetronitrile in 0.1% formic
acid at a ﬂow rate of 300 nL/min. Peptides were sampled on a
300 μm × 5 mm PepMap C18 precolumn and separated on a
75 μm × 250 mm C18 PepMap column (Thermo Fischer Scientiﬁc). MS
andMS/MS datawere acquired usingXcalibur (Thermo Fischer Scientif-
ic). Survey full-scanMS spectra (m/z=400–1600)were acquired in the
Orbitrap operated in positive mode with a resolution of 60,000 after
accumulation of 106 ions (maximum ﬁlling time: 500 ms). The ﬁfteen
most intense ionswere selected for fragmentation bymulti stage activa-
tion after accumulating ions to a target value of 5000 and a max. injec-
tion time of 100 ms. Data were automatically processed using Mascot
Daemon software (version 2.3,Matrix Science). Peak listswere generat-
ed with Mascot Distiller version 2.3.2.0 software (Matrix Science) from
the LC-MS/MS raw data. Searches against a homemade database
containing FADD and MBP sequences and against contaminants
database (658 sequences in total for these 2 databases) and the
corresponding reversed databases were performed using Mascot
(version 2.4). ESI-FTICR was chosen as the instrument, semitrypsin as
the enzyme and 2 missed cleavage allowed. Precursor and fragment
mass error tolerances were set respectively at 5 ppm and 1 Da. Peptide
modiﬁcations allowed during the search were as follows: carbamido-
methylation (C, ﬁxed) acetylation (protein N-term, variable), oxidation
(M, variable) and phosphorylation (S, T, Y, variable [36]). The IRMa
software (version 1.31.1) was used to ﬁlter results. Peptides with a
Mascot score above 30 were validated. Protein groups identiﬁed with
two different peptides and at least one proteotypic peptide were
furthermore validated.
2.8. Site directed mutagenesis
Site directed mutagenesis was performed using the QuickChange II
XL Site-Directed Mutagenesis Kit according to the manufacturer'sFig. 4. CK2 phosphorylates FADD on serine 200. A) Comparison of the cumulated mass spectr
unphosphorylated and phosphorylated sample. The zoom corresponds to the mass rang
SGAMSPMSWNSpDASTSEAS over the entire LC gradient between the non-phosphorylated and p
peptide. c) Phylogenetic tree and partial sequences enclosing the conserved serine 200 residueprotocol. Serine 200 was replaced by an alanine. Fwd primer: CCCCGA
TGTCATGGAACGCAGACGCATCTACCTCC and rev primer: GGAGGTAG
ATGCGTCTGCGTTCCATGACATCGGGG were used (underlined is the
modiﬁed amino acid sequence).
2.9. Plasmid vectors and transfection
The plasmid vector FADD-FLAG was kindly provided by Pr. Astar
Winoto (Division of Immunology and Pathogenesis, Department of
Molecular and Cell Biology, University of California, Berkeley, California,
USA). THP-1 cells were transfected with the FADD-FLAG using the
AMAXA kit V for immunoprecipitation assays and with the FADD-
FLAG/FADD-FLAG S200A with the Lipofectamine 2000 kit (Invitrogen)
for immunoﬂuorescence assays according to the manufacturers.
2.10. Statistical analysis
Statistical signiﬁcance was determined using Mann–Whitney non
parametric test or two-way ANOVA for multiple group analysis where
necessary. p ≤ 0.05 was considered as signiﬁcant.
3. Results
3.1. Nuclear FADD decreases after inhibition of CK2 activity
Given the importance of FADD sub-cellular localization on its cellular
activities, we searched for possible regulatory mechanisms involved in
its nuclear redistribution and restriction.While screening for regulatory
partners, we investigated the role of the protein kinase CK2, which is
already known to regulate proteins involved in the apoptotic process
[31,32]. We examined FADD localization in the myelomonocytic cell
line, THP1, in conditions where CK2 kinase activity was inhibited. We
carried out confocalmicroscopy experiments to investigate the localiza-
tion of endogenous FADD in resting and TBB-treated THP-1 cells. TBB is
a cell permeant highly selective, ATP/GTP-competitive inhibitor of
casein kinase-2 which binds to Val66 in the hydrophobic pocket,
precluding thereafter the binding of CK2 to ATP/GTP [37]. In non-
treated cells, FADD was localized mainly in the nucleus (Fig. 1A panel
a). At each time point following treatment with TBB (2 h, 12 h and
14 h), cells were washed and labeled with FADD antibody and DAPI.
We observed a signiﬁcant decrease of nuclear FADD concentration
upon treatment with TBB as observed after 14 h of TBB treatment
(Fig. 1A panel b). Quantiﬁcation results conﬁrmed that nuclear FADD
dropped off in presence of TBB as observedwith the signiﬁcant decrease
between the control and treated conditions (Fig. 1B). We did the same
experimentswith CX-4945, amore speciﬁc CK2 inhibitor. Again, nuclear
FADD decreased strongly (Fig. 1C panels a–c). Quantiﬁcation studiesum over the chromatographic elution peak of SGAMSPMSWNSpDASTSEAS between the
e of 985–1000 m/z. B) Comparison of extracted ion chromatogram for the peptide
hosphorylated samples. Arrows in bold represent peaks corresponding to phosphorylated
in different species.
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points studied, there was a signiﬁcant decrease in nuclear FADD after
2 h and 4 h of CX-4945 treatment (Fig. 1D—a and b). To support the
data obtained with immunoﬂuorescence studies, subcellular fraction-
ation of THP-1 cells were performed. THP-1 cells were treated with
TBB and protein extracts were prepared at the indicated time points
and resolved on SDS-PAGE. Ratio of FADD to cytoplasmic (actin) or
nuclear (p84) loading controls are given as arbitrary units. The results
show that there is an increase of FADD/actin ratio over timewhile a par-
allel decrease in the FADD/p84 ratio is observed (Fig. 1E, Supplemental
Fig. 1). Collectively, these results demonstrate that inhibition of CK2
activity induced a signiﬁcant decrease of nuclear FADD and suggest
that in THP-1 cells, CK2 activity could be necessary to restrict or to
maintain FADD localization inside the nucleus.
3.2. CK2 subunits and FADD colocalize into the nucleus
To understand whether the observed change in FADD distribution
upon CK2 inhibition could be explained by a direct interaction between
FADD and CK2, we conducted colocalization studies. It has been docu-
mented that CK2α and β subunits can be localized in the cytoplasm
and the nucleus, together or separately [38]. How, why and where the
CK2 subunits will interact is still under investigation [39]. In THP-1
cells, the regulatory and catalytic subunits of CK2 were localized in
both the cytoplasm and the nucleus albeit with a higher concentration
in the latter (Fig. 2A). In the merge pictures, colocalized pixels, in
white, showed that CK2 subunits and FADD colocalized exclusively in
the nucleus (Fig. 2B). The calculation of Pearson's correlation coefﬁcient
using the JaCoP plugin of ImageJ gave rise to high r values (0.93 for
FADD/CK2α and 0.84 for FADD/CK2β) (Fig. 2B). We carried out the
same experiments in Jurkat T lymphocytes cell line and observed a
similar nuclear colocalization of FADD and CK2 subunits (data not
shown). This colocalization raised the possibility that FADD and CK2
might interact as a molecular complex in living cells.
3.3. FADD is phosphorylated by the CK2 holoenzyme in a CK2β-dependent
manner
In light of the above results we investigatedwhether CK2 could bind
and phosphorylate FADD in vitro using recombinant CK2 subunits and
recombinant FADD (MBP-FADD). To determine whether CK2 subunits
bind directly to FADD, we performed in vitro binding assays. CK2α or
CK2β either individually or mixed together were incubated with
amylose beads loaded with MBP-FADD. Western blot analysis using
anti-MBP antibody showed that theMBP-FADD bound to both CK2 sub-
units (Fig. 3A). When CK2α or CK2β were mixed together to generate
the holoenzyme prior to incubation with MBP-FADD, a similar amount
of both CK2 subunits bound to the fusion protein indicating that
in vitro, both CK2 subunits interact with FADD individually (Fig. 3A).
To investigate whether or not CK2 could phosphorylate FADD in vitro,
MBP-FADD was incubated with CK2α or CK2β individually or with the
holoenzyme in the presence of [γ-32P]ATP/Mg. As shown in Fig. 3B
MBP-FADD was weakly phosphorylated by the isolated CK2α subunit
whereas its phosphorylation was strongly enhanced in the presence of
the holoenzyme. The 27 kDa band corresponded to autophosphoryla-
tion of the CK2β subunit in the holoenzyme complex [24]. We noticed
that only the higher form of the FADD protein at 60 kDa could be
phosphorylated. Given that MBP-FADD was bound to maltose resin for
the in vitro kinase assay, phosphorylation could take place only on the
C-terminal part of the recombinant protein. Furthermore, phosphoryla-
tion was potentiated with increasing concentrations of the CK2β
subunit and optimal phosphorylation was observed in the presence of
stoichiometric amounts of CK2 catalytic and regulatory subunits,
thereby showing that FADD phosphorylation is a CK2β driven process
(Fig. 3B and C). We also veriﬁed whether endogenous CK2, like
recombinant CK2, could bind and phosphorylate FADD. The polyanionicstructure of heparin allowed recovering CK2 kinase from the extracts
[40]. Therefore, we carried out heparin-sepharose afﬁnity chromatogra-
phy to pull-down the endogenous CK2 from THP-1 extracts and assess
its capacity to phosphorylate recombinant FADD. In these conditions,
recombinant FADD was also readily phosphorylated (Fig. 3D). More-
over, when the phosphorylation assay was carried out in the presence
of CX-4945, FADD was not phosphorylated anymore indicating that
endogenous CK2 served as a kinase for FADD phosphorylation. We
obtained the same results with CK2 brought down from Jurkat extract
(Supplemental Fig. 2). Thus, these results demonstrate that the CK2
tetrameric holoenzyme might be a FADD kinase.3.4. CK2 phosphorylates FADD on serine 200
Basic primary sequence analysis identiﬁed fourteen potential CK2
phosphorylation sites on human FADD protein (Table 1). To determine
the actual phosphorylation sites, we used tandem mass spectrometry
(MS/MS) experiments. We incubated MBP-FADD with recombinant
CK2 holoenzyme in the absence or presence of ATP-MgCl2. The proteins
were puriﬁed on SDS-PAGE and related bands were excised and
digested with trypsin. Resulting peptides mixtures were separated by
online reversed-phase nanoscale capillary LC and analyzed by ESI-MS/
MS. Confrontation of MS/MS spectra to protein databases by Mascot
software led to the identiﬁcation of FADD with more than 70% of
sequence coverage for both unphosphorylated and phosphorylated
samples. While for the unphosphorylated sample, no spectrum was
validated for any phosphorylated peptide, three spectra corresponding
to different oxidized forms of the same phosphorylated peptide
SGAMSPMSWNSDASTSEAS (from amino acid 190 to 208) were validat-
ed for the phosphorylated sample. As this peptide shows eight different
possible phosphorylation sites, we used site analysis based on Mascot
delta score [41] to correctly assign the phosphorylation site. The
different probabilities corresponding to the possible site assignations
are reported in Table 2 for each spectrum. Phosphorylation could be
localized to the serine 200with high probability for two of these spectra
(99.6% and 94.4%). Last spectrum gave same assignation but with a
lower probability. To conﬁrm the speciﬁcity of the CK2 activity and of
the identiﬁed phosphorylated peptide, we extracted the different
masses of its three forms from the chromatogram. Extracted ion
chromatogram of the non-oxidized form (m/z 991.86Th) showed that
this peptide is detected only in the phosphorylated sample (Fig. 4A).
Moreover, as shown on the mass spectrum cumulated over the elution
peak of this peptide (22.56–23.46 min), no ion corresponding to the
above peptide was detected in the unphosphorylated sample even
with a low intensity compared to the phosphorylated sample
(Fig. 4B). Comparison of hFADD protein sequence and non-human
primates and mouse FADD sequence showed that the serine 200 is
conserved, suggesting that this CK2-dependent FADD nuclear restric-
tion mechanism could be conserved in other organisms (Fig. 4C).3.5. Serine 200 is required for FADD nuclear retention
To test that S200 phosphorylation is necessary for FADD retention
in the nucleus, we observed the localization of FADDS200A in THP-1
cells. Site directed-mutagenesis was performed and plasmids bear-
ing either FADD-FLAG (FADDwt) or FADD200A-FLAG were used to
transfect THP-1 cells and followed by immunoﬂuorescence to detect
localization of FADDwt and FADDS200A. We observed that, as ex-
pected, FADD-FLAG showed nuclear and cytoplasmic expression
with a very high bias towards nuclear expression as we had seen
for endogenous FADD (Fig. 5A). FADD S200A showed high cytoplas-
mic expression (Fig. 5B). In fact, FADD seemed to be nearly complet-
ed excluded from the nucleus suggesting that serine 200 is important
for nuclear retention of FADD.
Fig. 5. Representative montages of comparison between FADD-FLAG (FADDwt) and FADD-S200A sub-cellular localizations in THP-1 cells. The cells were transfected with FADD-FLAG or
FADD-S200A and labeled as follows: anti-FLAG pAb (green) andDAPI (blue). Themontage show transfected FADD-FLAG (A) and FADD-S200A (B) cells from different experiments. Bars in
the inset represent 20 μm.
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Fig. 6. Representative images of comparison between FADD sub-cellular localizations inMCF10A-wt andMCF10A-ΔCK2β. Cells were grown on lab-tek slides and labeled as follows: anti-
FADD pAb (green), anti-CK2βmAb (red) and DAPI (blue). Two independent experiments were conducted. Thirty-two ﬁelds have been counted per experiment, each ﬁeld containing
around ﬁfteen cells. Sections of each overlay images are magniﬁed. Bars represent 15 μm.
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FADD loss
Since the presence of CK2β is crucial for FADD phosphorylation, we
used an immortalized human breast epithelial cell line, MCF10A-
ΔCK2β, in which expression of CK2β has been knocked down [42].
FADD localization was analyzed in MCF10A-wt and MCF10A-ΔCK2β
cells by confocal microscopy. As previously described by Screaton
et al. [18] FADD was localized mainly in the nucleus of the MCF10A-wt
(Fig. 6A). Similarly, CK2β was concentrated in the nucleus of the
MCF10A-wt (Fig. 6A). However, in MCF10A-ΔCK2β cells, the localiza-
tion of FADD was clearly shifted to the cytoplasm though some FADD
was also detected in the nucleus (Fig. 6B, see magniﬁcation). AsFig. 7. Schematic diagram of phosphorylation of FADD by the anti-apoptotic protein kinase CK
apoptotic protein upon its binding with the death receptor Fas and pro-caspase-8. Regarding F
CK1α, occurring in the cytoplasm, has already been described. This phosphorylation will allow
anism. Once, in the nucleus, FADD could bind to the CK2 holoenzyme, be further phosphorylated
factor or 2) FADD could bind to the CK2 holoenzyme in the cytoplasm ﬁrst. CK2αwould phosph
would be retained andwould act as an anti-apoptotic factor. TBB or CX4945 treatment will inhib
stances, FADD would not be retained anymore in the nucleus and would augment in the cytopexpected, the signal was null for CK2β (Fig. 6B). Merge of DAPI and
FADD disclosed that in conditions where CK2β expression was
downregulated, nuclear FADD was lost. These results corroborated
the results obtained in TBB- or CX-4945-treated THP-1 cells in
which CK2 activity was dramatically reduced. Given the requirement
of CK2β for optimal FADD phosphorylation, conditions found in
MCF10A-ΔCK2β cells mimicked somehow the effect observed in re-
sponse to drug-induced inhibition of CK2 catalytic activity. As al-
ready observed [42] CK2α was concentrated in the nucleus of
MCF10A-wt cells whereas the protein was mainly cytoplasmic for
MCF10A-ΔCK2β cells (data not shown). These results clearly sug-
gested that CK2 activity might play a role for nuclear localization of
FADD.2 and its effect on FADD sub-cellular localization. In the cytoplasm, FADD can act as a pro-
ADD nuclear localization, two scenarios could be possible: 1) Phosphorylation of FADD by
FADD to be shuttled from the cytoplasm to the nucleus via Exportin-5 dependent mech-
byCK2α on serine 200 and retained in the nucleuswhere itwould act as an anti-apoptotic
orylate FADD on serine 200 and thewhole complex would shuttle to the nucleus where it
it CK2, precluding FADD phosphorylation in the cytoplasm or the nucleus. In such circum-
lasm.
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In an attempt to identify possible regulators of FADD sub-cellular
localization we identiﬁed the anti-apoptotic kinase CK2 as a key actor.
We demonstrated for the ﬁrst time that CK2 activity inﬂuences FADD
localization (Fig. 1A–E) and that CK2 colocalizes with, binds and phos-
phorylates FADD in vitro (Fig. 2A, B, Fig 3A-C). It has previously been
reported as data not shown that recombinant CK2 could not
phosphorylate FADD [19]. One possibility to explain such discrepancy
is that the material and conditions used for the in vitro kinase assay
might have been detrimental somehow and did not allow for identiﬁca-
tion of phosphorylated FADD.One important observation is that optimal
phosphorylation was observed in the presence of stoichiometric
amounts of CK2 catalytic and regulatory subunits, thereby showing
that FADD phosphorylation is a CK2β driven process. Several studies
have shown that some substrates could be phosphorylated by CK2α
alone as it is spontaneously active [26]. However, the CK2 regulatory
subunit requirement for efﬁcient CK2-mediated FADD phosphorylation
is of interest since it has been reported that CK2β could serve as a scaf-
fold or docking platform to enhance the afﬁnity of CK2α for its substrate
[26,43]. Therefore, FADDbelongs to the growing list of CK2β-dependent
substrates. Importantly, endogenous CK2 isolated from THP-1 extracts
(Fig. 3D) as well as Jurkat cell extracts (data not shown) were efﬁcient
for in vitro phosphorylation of recombinant FADD (Fig. 3D) and this
phosphorylation was alleviated by the presence of CX-4945, the actual
most speciﬁc CK2 inhibitor. Of note, the CX-4945 is in a phase II clinical
trial in patients suffering of remitting multiple myelomas [44].
It is largely accepted that FADD requires nuclear positioning to carry
out its non-apoptotic functions [17]. It has been very elegantly demon-
strated by Alappat et al. that phosphorylation of FADD by CK1α on
serine 194 is essential for FADD nuclear localization. It is currently
unclear whether FADD is phosphorylated ﬁrst and then sent to the
nucleus or whether FADD travels to the nucleus via binding to CK1α
and undergoes post-translational modiﬁcations once there [17]. Herein,
we brought evidence that FADD phosphorylation by CK2 might be
important to keep FADD in the nucleus. Under conditions where CK2
activity was hampered either by pharmacological means or by CK2β
subunit expression knock-down, nuclear FADD was strongly decreased
(Fig. 6). It is known that FADD is not located similarly in all cell lines.
How important is the role of CK2 in every type of cells regarding
FADD sub-cellular localization is beyond the scope of this report. The
fact that co-localization of FADD and CK2 was restricted to the nucleus
is of signiﬁcance since a large number of CK2 substrates are found in
the nucleus andmany of these are usually DNA/RNA structural proteins
and transcription factors [39]. It is known that nuclear CK2 is correlated
with apoptosis resistancewhichmight be reminiscent of a potential role
of CK2 in FADDanti-apoptotic activities [29].We found that in condition
where TBB is added to THP-1 cells, the latter showed a higher sensitivity
to cell death (unpublished). We found the same results in MCF10A-
ΔCK2β. These results are in line with our data that CK2, once inhibited
could cause nuclear FADD loss and therefore potentially more FADD at
the death inducing signaling complex (DISC). However we cannot rule
out the possibility that other functions of CK2, independently of its ef-
fect on FADD,might cause increased cell death in condition of inhibition.
Evidence has shown that FADD can bind toMBD-4 protein in the nucle-
us [18] and thus participate in genome surveillance through a mecha-
nism which still needs to be understood. Such a mechanism might be
involved in a CK2-driven FADD anti-apoptotic activity or along this
line, a mechanism which might recruit CK2, FADD as well as MBD-4.
Serine 200 was identiﬁed by mass spectrometry analysis identiﬁed
as the actual phosphorylation site of CK2 in the FADD protein (Fig. 4A,
B, Table 2). This residue does not lie within a S/T-X-X-D/E canonical
CK2 phosphorylation site (Table 1), where X might be any residue and
where the most important residue is the acidic residue at n + 3.
However, while a majority of the proteins phosphorylated by CK2
have an acidic residue at n + 3, the second most important position isthe presence of an acidic residue at n + 1 [25] like in the case of FADD
therefore reinforcing the accuracy of the identiﬁed serine. Phylogenetic
comparison showed that this serine is conserved not only among higher
primates but also in mice suggesting a possible important role for this
residue in FADD regulation (Fig. 4C). Mass spectrometry analysis were
reinforced by site-directed mutagenesis. Indeed FADDS200A abolished
the function of CK2 on FADD nuclear localization (Fig. 5B). These data
are consistent with the conservation of the serine 200 during evolution.
We therefore propose a possible scheme whereby CK1 binding and
phosphorylation of FADD would allow the latter to enter the nucleus.
Once there, further phosphorylation by CK2 could lead to sequestering
of FADD inside this organelle in order to keep it away from the death
receptors thus down-regulating apoptosis (Fig. 7).
In conclusion, our results show for the ﬁrst time amolecular interac-
tion between CK2 and FADD and we suggest that this interaction could
play a role in FADD nuclear localization. Perspective work would be
required to identify whether a possible dialogue could exist between
CK1- and CK2-mediated phosphorylation of FADD and to dig further
the signiﬁcance of this interaction to the cell processes. While our data
show that FADD is phosphorylated on serine 200 by the CK2 kinase,
we still don't know where, within the cell, the phosphorylation process
occurs.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2015.08.001.
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